Post Traumatic Stress Disorder Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Key Companies – Pfizer, GlaxoSmithKline, KGK Science Inc.

 Breaking News
  • No posts were found

Post Traumatic Stress Disorder Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Key Companies – Pfizer, GlaxoSmithKline, KGK Science Inc.

May 10
19:40 2023
Post Traumatic Stress Disorder Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight |  Key Companies - Pfizer, GlaxoSmithKline, KGK Science Inc.
DelveInsight’s “Post Traumatic Stress Disorder Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Post Traumatic Stress Disorder.

DelveInsight’s “Post Traumatic Stress Disorder Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Post Traumatic Stress Disorder, historical and forecasted epidemiology as well as the Post Traumatic Stress Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Post Traumatic Stress Disorder market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Post Traumatic Stress Disorder Market Forecast

 

Some of the key facts of the Post Traumatic Stress Disorder Market Report: 

  • The Post Traumatic Stress Disorder market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • When it comes to disasters and accidents, women are more likely than males to get PTSD. The prevalence is more than twice as high in women as it is in men, with women showing a prevalence of 33.2% compared to men’s 14.5%
  • Thirty percent of emergency medicine (EM) residents had symptoms that did not match the diagnostic standard for PTSD, according to a single-site study by the American Psychiatric Association in the U.S. Eleven percent of EM residents met the criteria for PTSD
  • Key Post Traumatic Stress Disorder Companies: Nobilis Therapeutics, Otsuka Pharma, Compass Pathways, Aptinyx, Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, GlaxoSmithKline, KGK Science Inc., AstraZeneca, UCB Pharma, Bionorica SE, Bionomics Limited, Pfizer, and others
  • Key Post Traumatic Stress Disorder Therapies: NBTX001, Brexpiprazole, COMP360, NYX-783, JZP150, Psilocybin, BNC210, BI 1358894, orvepitant, Psilocybin, Quetiapine Fumarate, levetiracetam, BX-1, BNC210, Ziprasidone, and others
  • The Post Traumatic Stress Disorder epidemiology based on gender analyzed that females are more affected with PTSD than females
  • The Post Traumatic Stress Disorder market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Post Traumatic Stress Disorder pipeline products will significantly revolutionize the Post Traumatic Stress Disorder market dynamics.

 

Post Traumatic Stress Disorder Overview

A person who has experienced or witnessed a traumatic event, such as a natural disaster, a serious accident, a terrorist act, war or combat, or rape, or who has been threatened with death, or serious injury, may develop post-traumatic stress disorder (PTSD), a chronic psychiatric disorder.

 

Get a Free sample for the Post Traumatic Stress Disorder Market Report – 

https://www.delveinsight.com/sample-request/post-traumatic-stress-disorder-ptsd-market

 

Post Traumatic Stress Disorder Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Post Traumatic Stress Disorder Epidemiology Segmentation:

The Post Traumatic Stress Disorder market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Post Traumatic Stress Disorder
  • Prevalent Cases of Post Traumatic Stress Disorder by severity
  • Gender-specific Prevalence of Post Traumatic Stress Disorder
  • Diagnosed Cases of Episodic and Chronic Post Traumatic Stress Disorder

 

Download the report to understand which factors are driving Post Traumatic Stress Disorder epidemiology trends @ Post Traumatic Stress Disorder Epidemiology Forecast

 

Post Traumatic Stress Disorder Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Post Traumatic Stress Disorder market or expected to get launched during the study period. The analysis covers Post Traumatic Stress Disorder market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Post Traumatic Stress Disorder Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Post Traumatic Stress Disorder Therapies and Key Companies

  • NBTX001: Nobilis Therapeutics
  • Brexpiprazole: Otsuka Pharma
  • COMP360: Compass Pathways
  • NYX-783: Aptinyx
  • JZP150: Jazz Pharmaceuticals
  • Psilocybin: COMPASS Pathways
  • BNC210: Bionomics Limited
  • BI 1358894: Boehringer Ingelheim
  • orvepitant: GlaxoSmithKline
  • Psilocybin: KGK Science Inc.
  • Quetiapine Fumarate: AstraZeneca
  • levetiracetam: UCB Pharma
  • BX-1: Bionorica SE
  • BNC210: Bionomics Limited
  • Ziprasidone: Pfizer

 

Discover more about therapies set to grab major Post Traumatic Stress Disorder market share @ Post Traumatic Stress Disorder Treatment Market

 

Post Traumatic Stress Disorder Market Strengths

  • Post Traumatic Stress Disorder is a frequently used modality for cancer treatment. As a result, a huge population suffers from Post-Traumatic Stress Disorder, which presents a huge market to any new entrant
  • The diagnosis of the disorder is easy with a clear clinical presentation, which helps in identifying the disease

 

Post Traumatic Stress Disorder Market Barriers

  • Challenge in recognition of condition
  • Development of novel therapies
  • Limited availability in services
  • Poor disease understanding
  • Development of effective treatment

 

Scope of the Post Traumatic Stress Disorder Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Post Traumatic Stress Disorder Companies: Nobilis Therapeutics, Otsuka Pharma, Compass Pathways, Aptinyx, Jazz Pharmaceuticals, COMPASS Pathways, Bionomics Limited, Boehringer Ingelheim, GlaxoSmithKline, KGK Science Inc., AstraZeneca, UCB Pharma, Bionorica SE, Bionomics Limited, Pfizer, and others
  • Key Post Traumatic Stress Disorder Therapies: NBTX001, Brexpiprazole, COMP360, NYX-783, JZP150, Psilocybin, BNC210, BI 1358894, orvepitant, Psilocybin, Quetiapine Fumarate, levetiracetam, BX-1, BNC210, Ziprasidone, and others
  • Post Traumatic Stress Disorder Therapeutic Assessment: Post Traumatic Stress Disorder current marketed and Post Traumatic Stress Disorder emerging therapies
  • Post Traumatic Stress Disorder Market Dynamics: Post Traumatic Stress Disorder market drivers and Post Traumatic Stress Disorder market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Post Traumatic Stress Disorder Unmet Needs, KOL’s views, Analyst’s views, Post Traumatic Stress Disorder Market Access and Reimbursement 

 

To know more about Post Traumatic Stress Disorder companies working in the treatment market, visit @ Post Traumatic Stress Disorder Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Post Traumatic Stress Disorder Market Report Introduction

2. Executive Summary for Post Traumatic Stress Disorder

3. SWOT analysis of Post Traumatic Stress Disorder

4. Post Traumatic Stress Disorder Patient Share (%) Overview at a Glance

5. Post Traumatic Stress Disorder Market Overview at a Glance

6. Post Traumatic Stress Disorder Disease Background and Overview

7. Post Traumatic Stress Disorder Epidemiology and Patient Population

8. Country-Specific Patient Population of Post Traumatic Stress Disorder 

9. Post Traumatic Stress Disorder Current Treatment and Medical Practices

10. Post Traumatic Stress Disorder Unmet Needs

11. Post Traumatic Stress Disorder Emerging Therapies

12. Post Traumatic Stress Disorder Market Outlook

13. Country-Wise Post Traumatic Stress Disorder Market Analysis (2019–2032)

14. Post Traumatic Stress Disorder Market Access and Reimbursement of Therapies

15. Post Traumatic Stress Disorder Market Drivers

16. Post Traumatic Stress Disorder Market Barriers

17.  Post Traumatic Stress Disorder Appendix

18. Post Traumatic Stress Disorder Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services

Categories